TESARO is an oncology-focused biopharmaceutical company. The company acquires, in-licenses and develops oncology product candidates. The company has in-licensed and is developing oncology-related product candidates, including rolapitant, niraparib, and the product candidates under its immuno-oncology platform. The company's existing products and product candidates are: Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an oral poly polymerase inhibitor for the treatment of ovarian or breast cancers; and Immuno-Oncology Platform, which is engaged in the discovery and development of antibodies for several immuno-oncology targets.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.